Skip to main content

Table 3 Univariate Cox proportional hazard regression models of biochemical recurrence free survival (n = 15)

From: Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trial

  Univariate
Variable Hazard ratio 95 % index p value
Age (≥74 vs. <74) 3.9 0.57–75 0.18
Serum PSA (ng/mL) (≥198 vs. <198) 1.9 0.33–15 0.45
J-CAPRA (≥9 vs. ≤8) 1.7 0.27–12 0.57
AR LI (≥93.5 vs. <93.5) 1.2 0.19–8.7 0.87
ERα LI (≥23.2 vs. <23.2) 0.40 0.05–2.5 0.32
ERβ LI (≥16.1 vs. <16.1) 0.73 0.09–4.4 0.73
TOPADT vs. MAB 1.1 e−9 0.64–0.64 0.023
RAPADT vs. MAB 0.5 0.069–3.2 0.48
\